[Asia Economy Reporter Kim Ji-hee] Bukwang Pharmaceutical announced on the 17th that it is making company-wide efforts to ensure smooth supply due to increased demand for the acetaminophen-based 'Tasenol' product line, which is used to relieve fever and pain after vaccination.
Recently, interest has been focused on acetaminophen-containing antipyretics as vaccine standby medicine along with COVID-19 vaccination. This is due to the recommendations for acetaminophen by the Korea Disease Control and Prevention Agency and the Korean Medical Association.
According to Bukwang Pharmaceutical, inquiries from pharmacies seeking to supply the acetaminophen product Tasenol are also continuing. Especially for small packages, market demand is significantly higher than supply due to COVID-19 vaccination. Bukwang Pharmaceutical carries out all manufacturing processes of the Tasenol product line directly at its own factory.
A representative from Bukwang Pharmaceutical stated, "To establish a stable supply chain for the Tasenol product line, we are prioritizing the production capacity of our factory on the Tasenol product line and doing our best to improve supply speed."
Tasenol is a single-ingredient acetaminophen product, produced and sold directly by Bukwang Pharmaceutical. It consists of two product lines: Tasenol Tablets 500mg, a fast-acting product focused on rapid symptom relief, and Tasenol 8-Hour ER Sustained-Release Tablets, a dual-release type with lasting effects.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
